IZOZF - Initial Insurance Billing Codes Issued for Dedicated Breast CT in the USA
(TheNewswire)
VANCOUVER, BC - TheNewswire - March 4, 2021 - Izotropic Corporation (“ Izotropic ”) (C NSX : IZO. CN ) (OTC: IZOZF )(FSE: 1R3 ), a company developing high-resolution 3D dedicated breastCT imaging technology for the earlier detection, diagnosis, andtreatment of breast cancers, is pleased that the American MedicalAssociation (AMA) has released six Category III CPT billing codes forBreast CT technology.
The AMA i ssuance of these initialinsurance billing codes spotlights dedicated breast CT as a promisingemerging technology. It is an important development and step in thereimbursement process and aligns with Izotropic’s activities inworking with payors to secure future coverage.
Izotropic’s imaging technology is based on technologyfrom Dr. John M. Boone’s laboratory at UC Davis, with prototypedevices used in a number of fully-funded clinical trials, the resultsof which have been published in peer reviewed literature. Izotropic is now engaged with key payors in the USA to definetheir acceptance criteria and the timelines involved in obtainingcoverage for breast CT. P ayors may use Dr. Boone’s historic and ongoing breast CTimaging clinical trial data in addition to Izotropic’s futureclinical data to support insurance coverage decisions.
Izotropic continues to work towards commercializing itsbreast CT imaging technology for the earlier detection, diagnosis, andtreatment of breast cancers. The AMA issuance of these initialinsurance billing codes is one more positive step along thatpath.
ON BEHALF OF THE BOARD
Robert Thast, CEO
For investor relations inquiriescontact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
Background: Category III CPTCodes Defined
Category III CPT codes are temporary codes for emergingtechnologies and are used to facilitate data collection and trackperformance. These codes usually remain active for five years. Themain difference between a Category I and a Category III codeapplication is that a Category III code application does not requireFDA approval/clearance or proven clinical efficacy.
A Category III code needs to satisfy specific criteria. The procedure or service must be currently or recently performed inhumans. Also, the procedure or service has to meet at least one ofthe following additional criteria (“The CPT ApprovalProcess”):
-
- Supported by at least one CPT or Health CareProfessionals Advisory Committee (HCPAC, whose members representqualified non-physician healthcare professionals) society that woulduse this procedure or service
- Actual or potential clinical efficacy supported bypeer-reviewed literature
- At least one institutional review board (IRB)approved protocol of a study
- A description of a current and ongoing United Statestrial outlining the efficacy
About Izotropic Corporation
Izotropic Corporation is commercializing dedicatedbreast CT imaging technology for the earlier detection, diagnosis andtreatment of breast cancers. Extensive preliminary studies have foundthat breast CT may be able to routinely detect small breast tumors inthe 3-5 mm size range. The median size of breast cancer found usingmammography is approximately 11 mm. Routine detection of 3 mm lesionswould result in 1.5 year earlier detection over mammography.
The initial indication for use for breast CT as adiagnostic device has been confirmed. Forthcoming business objectivesinclude identifying additional indications for use, development ofaccessories, and additional products, all aimed at making breast CT anindispensable tool for improving the outcomes of breast cancer.
Additional infor mation aboutIzotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward Looking Statements
This document may contain statements that are“Forward-Looking Statements,” which are based upon the currentestimates, assumptions, projections and expectations of thecompany’s management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify such information and statements byusing words such as “anticipate,” “believe,” “envision,”“estimate,” “expect,” “intend,” “may,” “plan,”“predict,” “project,” “target,” “potential,”“will,” “would,” “could,” “should,” “continue,”“contemplate” and other similar expressions and derivationsthereof in connection with any discussion of future events, trends orprospects or future operating or financial performance, although notall forward-looking statements contain these identifying words. Thesestatements are not guarantees of performance and involve risks anduncertainties that are difficult to control or predict, and as suchthey may cause future results of the company’s activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstancesunless otherwise required to do so by law. Neither the company nor its shareholders, officers andconsultants, shall be liable for any action and the results of anyaction taken by any person based on the information contained herein,including without limitation the purchase or sale of companysecurities. Nothing in this document should be deemed to be medical orother advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.